-+ 0.00%
-+ 0.00%
-+ 0.00%

Xinlitai (002294.SZ): SAL0140 approved for clinical trials

Zhitongcaijing·12/08/2025 11:17:09
Listen to the news

Zhitong Finance App News, Xinlitai (002294.SZ) announced that the company received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration and agreed to carry out clinical trials of the innovative small molecule drug SAL0140 tablets (project code: SAL0140) independently developed by the company to treat primary hyperaldosteronism.

According to the announcement, SAL0140 is an aldosterone synthase inhibitor with the company's independent intellectual property rights. Indications for development include uncontrolled high blood pressure (including intractable hypertension), primary hyperaldosteronism, and chronic kidney disease (CKD).